Creation of a Fibroblast/iPS Cell Bank to Facilitate Peripheral/Brain Comparisons, and Allow Molecular Investigations into Molecular Mechanisms Underlying Differences in Disease Aggressiveness

An astonishing discovery of how to convert skin cells into other kinds of cells—including brain cells—earned Dr. Shinya Yamanaka the Nobel prize in 2012 and already has opened extraordinary new capabilities in science. Applied to Alzheimer’s disease, it has the potential to revolutionize how we do experiments. Right now, we ...

November 5, 2020

Bradley T. Hyman

Understanding and Mimicking the Biological Effects of the Phospholipase C-gamma-2 P522R Variant That Protects Against Alzheimer’s Disease

The cause of Alzheimer’s disease remains unknown. However, thanks to the progress of genomic-wide association analysis, where genetic sequences are studied in big populations and related to the incidence of diseases, new genetic risk factors and genetic protective factors have been identified. Among those, it recently was shown that a ...

January 29, 2021

Philip Scheltens, Rik van der Kant

$5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private ...

October 18, 2012

Scaling Heights to Cure Alzheimer’s

Mountaineer to Raise Awarness, Research Funding for Alzheimer’s on Road Back to Everest Boston – Embarking on a yearlong challenge that he hopes will end at the top of Mt. Everest, mountain climber Alan Arnette will take on a greater challenge along his journey, raising money for research and public awareness ...

August 20, 2009

Understanding Reactive Astrocytes and Their Roles in Alzheimer’s Disease

We are investigating the mechanisms that cause neurodegeneration in Alzheimer’s disease. Our recent studies have led us to realize that a toxic protein is unexpectedly secreted by a class of brain cells called astrocytes in the setting of Alzheimer’s disease. Our goal in this proposal is to identify this protein ...

September 28, 2015

Ben Barres

One Person Can Make a Difference

Jessica Lavorgna, age 11, from Tewksbury, NJ is raising money for Cure Alzheimer’s Fund for her 6th grade class project. Each student was asked to develop a project that somehow changes or improves our world. While some of Jessica’s classmates wrote letters to soldiers in Iraq or volunteered time at a ...

August 20, 2009

Cure Alzheimer’s Fund Receives 4th Consecutive 4-Star Rating on Charity Navigator

For the fourth year in a row, Cure Alzheimer’s Fund has received a 4-star rating – the highest possible – from watchdog organization Charity Navigator. Charity Navigator rates over 8,000 nonprofits on many aspects of their accountability, transparency and fiscal responsibility. “Receiving four out of a possible four stars indicates that your organization adheres to ...

April 2, 2015

MassGeneral Honors Cure Alzheimer’s Fund with the “Philanthropic Innovation and Investment” Award

Massachusetts General Hospital and the MassGeneral Institute for Neurodegenerative Disease (MIND) has honored Cure Alzheimer’s Fund for its leadership, entrepreneurial philanthropy and investment in research projects that have the highest probability of slowing, stopping or reversing Alzheimer’s disease. The first annual Award for Philanthropic Innovation and Investment was presented to the ...

April 16, 2007

Do Classical Complement Activation and the Route of Administration of Anti-Amyloid Antibodies Contribute to Vascular Side Effects Known as Amyloid-Related Imaging Abnormalities?

Amyloid beta protein accumulates outside of neurons into plaques and within blood vessel walls inside the brain. Recently, two anti-amyloid antibodies, aducanumab (Biogen’s Aduhelm) and lecanemab (Eisai’s Leqembi), have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of early-stage Alzheimer’s disease (AD). A third antibody, ...

February 1, 2024

Cynthia A. Lemere

Marc Aurel Busche

Dr. Busche is a Programme Leader at the UK Dementia Research Institute (UK DRI) at University College London (UCL), where he leads a research effort focused on understanding the cellular and circuit mechanisms of Alzheimer’s Disease and related disorders. He also provides patient care as an honorary consultant psychiatrist in ...

November 22, 2023

Marc Aurel Busche, Samuel Harris